---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016487"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T14:16:37.659662+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# DiaMedica reports Q1 net loss $7.7M; preeclampsia Phase 2 topline data expected June-July 2025

## Summary
- Net loss $7.7M ($0.18/sh) vs $5.2M ($0.14) in Q1 2024; R&D expense rose to $5.7M on trial expansion.
- Cash $37.3M as of Mar 31, 2025 (down from $44.1M Dec 2024); runway into Q3 2026.
- Phase 2 preeclampsia Part 1A topline results expected between 2H June and 1H July 2025; KOL event May 28.
- ReMEDy2 stroke trial enrollment progressing; interim analysis on first 200 patients expected H1 2026.

## SEC filing metadata
- accession: 0001437749-25-016487
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774925016487/0001437749-25-016487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774925016487/dmtp20250512_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016487
- JSON: https://secwatch.observer/filing/0001437749-25-016487.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.